Biomimetic nanosystems based on cell membranes (BNCMs) for cancer immunotherapy

Abstract

With the development of nanosystems, they are gradually utilized to ameliorate diverse cancer therapies. Specifically for immunotherapy, most nanosystems are elaborately designed to initiate the self-sustaining “cancer immunity cycle (CIC)” to elicit the immune response. However, owing to the highly complex circulatory environment, nanosystems may face issues like nonspecific nanoparticle uptake and rapid clearance, leaving enormous room for advancement. For employing the biomimetic design in nanosystems, biomimetic nanosystems based on cell membranes (BNCMs) inherit various functional molecules from source cells, permitting precise tumor targeting, enhancing blood circulation, and conferring more desired functionality for a more robust immune response. To take full advantage of the BNCMs, understanding their functions in cancer immunotherapy is essential. In this review, the unique properties of BNCMs derived from various cells and main preparation strategies are introduced. Subsequently, the recent advances of BNCMs for improving cancer immunotherapy are discussed from the aspects of their roles in particular stages of the CIC, and the working mechanisms of the outer cell membranes are highlighted. Finally, along with the analysis of existing bottlenecks for clinical translation, some suggestions for the future development of BNCMs are put forward.

Keywords

biomimetic nanosystems / cancer immunity cycle / cell membrane / immunotherapy / tumor

References

[1] LingSP, MingLC, DhaliwalJS, et al. Role of immunotherapy in the treatment of cancer: a systematic review. Cancers. 2022;14(21):5205.

[2] HodiFS, O’DaySteven, SJ, McDermottDavid,DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.

[3] RobertC, LongGV, BradyB, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330.

[4] HamidO, RobertC, DaudA, et al. Safety and tumor responses with lambrolizumab (Anti–PD-1) in melanoma. N Engl J Med. 2013;369(2):134-144.

[5] BrentjensRJ, DavilaML, RiviereI, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra138.

[6] MullardA. FDA approves first CAR T therapy. Nat Rev Drug Discovery. 2017;16(10):669669.

[7] KalosM, LevineBL, PorterDL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.

[8] NamJ, SonS, ParkKS, Zou W, SheaLD, MoonJJ. Cancer nanomedicine for combination cancer immunotherapy. Nat Rev Mater. 2019;4(6):398-414.

[9] LuoZ, HeT, LiuP, et al. Self-adjuvanted molecular activator (SeaMac) nanovaccines promote cancer immunotherapy. Adv Healthcare Mater. 2021;10(7):e2002080.

[10] LiangX, LiX, WuR, et al. Breaking the tumor chronic inflammation balance with a programmable release and multi-stimulation engineering scaffold for potent immunotherapy. Adv Sci. 2024;11(28):e2401377.

[11] WhitesideTL, Demaria S, Rodriguez-RuizME, ZarourHM, MeleroI. Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res. 2016;22(8):1845-1855.

[12] MoradG, Helmink BA, SharmaP, WargoJA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309-5337.

[13] RobertC. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801.

[14] KennedyLB, SalamaAKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86-104.

[15] MorrisEC, Neelapu SS, GiavridisT, SadelainM. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85-96.

[16] KumarV, Chaudhary N, GargM, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49.

[17] LuoR, LeH, WuQ, GongC. Nanoplatform-based in vivo gene delivery systems for cancer therapy. Small. 2024;20(30):2312153.

[18] ToyR, RoyK. Engineering nanoparticles to overcome barriers to immunotherapy. Bioeng Transl Med. 2016;1(1):47-62.

[19] YanS, LuoZ, LiZ, et al. Improving cancer immunotherapy outcomes using biomaterials. Angew Chem Int Ed. 2020;59(40):17332-17343.

[20] HuangX, OuC, ShuY, et al. A self-sustained nanoplatform reverses TRAIL-resistance of pancreatic cancer through coactivating of exogenous and endogenous apoptotic pathway. Biomaterials. 2021;272:120795.

[21] WangX, IshidaT, KiwadaH. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Controlled Release. 2007;119(2):236-244.

[22] IchiharaM, Shimizu T, ImotoA, et al. Anti-PEG IgM response against PEGylated liposomes in mice and rats. Pharmaceutics. 2011;3(1):1-11.

[23] SuzukiT, SuzukiY, HiharaT, et al. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: faster PEG shedding attenuates anti-PEG IgM production. Int J Pharm. 2020;588:119792.

[24] RazaF, ZafarH, ZhangS, et al. Recent advances in cell membrane-derived biomimetic nanotechnology for cancer immunotherapy. Adv Healthcare Mater. 2021;10(6):e2002081.

[25] TieY, ZhengH, HeZ, et al. Targeting folate receptor β positive tumor-associated macrophages in lung cancer with a folate-modified liposomal complex. Signal Transduct Target Ther. 2020;5(1):6.

[26] ChengH-B, DaiH, TanX, et al. A facile, protein-derived supramolecular theranostic strategy for multimodal-imaging-guided photodynamic and photothermal immunotherapy in vivo. Adv Mater. 2022;34(11):e2109111.

[27] ChenQ, LiuZ. Albumin carriers for cancer theranostics: a conventional platform with new promise. Adv Mater. 2016;28(47):10557-10566.

[28] YangG, PhuaSZF, LimWQ, et al. A hypoxia-responsive albumin-based nanosystem for deep tumor penetration and excellent therapeutic efficacy. Adv Mater. 2019;31(25):e1901513.

[29] ElzoghbyAO, Abdelmoneem MA, HassaninIA, et al. Lactoferrin, a multi-functional glycoprotein: active therapeutic, drug nanocarrier & targeting ligand. Biomaterials. 2020;263:120355.

[30] WuY, XieH, LiY, et al. Nitric oxide-loaded bioinspired lipoprotein normalizes tumor vessels to improve intratumor delivery and chemotherapy of albumin-bound paclitaxel nanoparticles. Nano Lett. 2023;23(3):939-947.

[31] FangRH, KrollAV, GaoW, ZhangL. Cell membrane coating nanotechnology. Adv Mater. 2018;30(23):e1706759.

[32] ZengZ, PuK. Improving cancer immunotherapy by cell membrane-camouflaged nanoparticles. Adv Funct Mater. 2020;30(43):e2004397.

[33] YuX, ShaL, LiuQ, et al. Recent advances in cell membrane camouflage-based biosensing application. Biosens Bioelectron. 2021;194:113623.

[34] LiuY, WengL, WangY, et al. Deciphering the role of CD47 in cancer immunotherapy. J Adv Res. 2024;63:129-158.

[35] HuC-MJ, ZhangL, AryalS, Cheung C, FangRH, ZhangL. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA. 2011;108(27):10980-10985.

[36] ZengY, LiS, ZhangS, Wang L, YuanH, HuF. Cell membrane coated-nanoparticles for cancer immunotherapy. Acta Pharm Sin B. 2022;12(8):3233-3254.

[37] WangJ, ZhuM, NieG. Biomembrane-based nanostructures for cancer targeting and therapy: from synthetic liposomes to natural biomembranes and membrane-vesicles. Adv Drug Deliv Rev. 2021;178:113974.

[38] RaoL, BuL-L, XuJ-H, et al. Red blood cell membrane as a biomimetic nanocoating for prolonged circulation time and reduced accelerated blood clearance. Small. 2015;11(46):6225-6236.

[39] MiwaT, ZhouL, HilliardB, Molina H, SongW-C. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack. Blood. 2002;99(10):3707-3716.

[40] ZalmanLS, WoodLM, Müller-EberhardHJ. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci USA. 1986;83(18):6975-6979.

[41] DaviesA, Simmons DL, HaleG, et al. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med. 1989;170(3):637-654.

[42] OldenborgP-A, Zheleznyak A, FangY-F, LagenaurCF, Gresham HD, LindbergFP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288(5473):2051-2054.

[43] YangZ, GaoD, GuoX, et al. Fighting immune cold and reprogramming immunosuppressive tumor microenvironment with red blood cell membrane-camouflaged nanobullets. ACS Nano. 2020;14(12):17442-17457.

[44] LiT, SongR, SunF, et al. Bioinspired magnetic nanocomplexes amplifying STING activation of tumor-associated macrophages to potentiate cancer immunotherapy. Nano Today. 2022;43:101400.

[45] SongQ, YinY, ShangL, et al. Tumor microenvironment responsive nanogel for the combinatorial antitumor effect of chemotherapy and immunotherapy. Nano Lett. 2017;17(10):6366-6375.

[46] XieH, LiW, LiuH, et al. Erythrocyte membrane-coated invisible acoustic-sensitive nanoparticle for inducing tumor thrombotic infarction by precisely damaging tumor vascular endothelium. Small. 2022;18(30):2201933.

[47] WuT, LangT, ZhengC, et al. Promote intratumoral drug release and penetration to counteract docetaxel-induced metastasis by photosensitizer-modified red blood cell membrane-coated nanoparticle. Adv Funct Mater. 2023;33(7):e2212109.

[48] LiJ, HuangX, HuangR, et al. Erythrocyte membrane camouflaged graphene oxide for tumor-targeted photothermal-chemotherapy. Carbon. 2019;146:660-670.

[49] WangH, WuJ, WilliamsGR, et al. Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery. J Nanobiotechnology. 2019;17(1):60.

[50] OlssonM, BruhnsP, FrazierWA, Ravetch JV, OldenborgP-A. Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. Blood. 2005;105(9):3577-3582.

[51] HuQ, SunW, QianC, Wang C, BombaHN, GuZ. Anticancer platelet-mimicking nanovehicles. Adv Mater. 2015;27(44):7043-7050.

[52] SimsPJ, Rollins SA, WiedmerT. Regulatory control of complement on blood platelets. J Biol Chem. 1989;264(32):19228-19235.

[53] WangS, DuanY, ZhangQ, et al. Drug targeting via platelet membrane–coated nanoparticles. Small Structures. 2020;1(1):2000018.

[54] LiB, ChuT, WeiJ, et al. Platelet-membrane-coated nanoparticles enable vascular disrupting agent combining anti-angiogenic drug for improved tumor vessel impairment. Nano Lett. 2021;21(6):2588-2595.

[55] BuL-L, RaoL, YuG-T, et al. Cancer stem cell-platelet hybrid membrane-coated magnetic nanoparticles for enhanced photothermal therapy of head and neck squamous cell carcinoma. Adv Funct Mater. 2019;29(10):e1807733.

[56] RaoL, MengQ-F, HuangQ, et al. Platelet–leukocyte hybrid membrane-coated immunomagnetic beads for highly efficient and highly specific isolation of circulating tumor cells. Adv Funct Mater. 2018;28(34):e1803531.

[57] ZhuangJ, GongH, ZhouJ, et al. Targeted gene silencing in vivo by platelet membrane–coated metal-organic framework nanoparticles. Sci Adv. 2020;6(13):eaaz6108.

[58] DehainiD, WeiX, FangRH, et al. Erythrocyte–platelet hybrid membrane coating for enhanced nanoparticle functionalization. Adv Mater. 2017;29(16):e1606209.

[59] JiangQ, WangK, ZhangX, et al. Platelet membrane-camouflaged magnetic nanoparticles for Ferroptosis-Enhanced cancer immunotherapy. Small. 2020;16(22):2001704.

[60] WangH, WuC, TongX, Chen S. A biomimetic metal-organic framework nanosystem modulates immunosuppressive tumor microenvironment metabolism to amplify immunotherapy. J Controlled Release. 2023;353:727-737.

[61] WangH, ZangJ, ZhaoZ, Zhang Q, ChenS. The advances of neutrophil-derived effective drug delivery systems: a key review of managing tumors and inflammation. Int J Nanomedicine. 2021;16:7663-7681.

[62] ZhangR-Y, ChengK, SunX, et al. Biomimetic O2 self-generated hybrid membrane nanoplatform for blocking the polarization towards immunosuppressive M2 macrophage phenotype and enhancing sonodynamics therapy in orthotopic colorectal cancer. Chem Eng J. 2022;450:138337.

[63] LiS, WangQ, ShenY, et al. Pseudoneutrophil cytokine sponges disrupt myeloid expansion and tumor trafficking to improve cancer immunotherapy. Nano Lett. 2020;20(1):242-251.

[64] ZhangQ, Dehaini D, ZhangY, et al. Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. Nat Nanotechnol. 2018;13(12):1182-1190.

[65] WuX, LinZ, ZhaoC, et al. Neutrophil membrane-coated immunomagnetic nanoparticles for efficient isolation and analysis of circulating tumor cells. Biosens Bioelectron. 2022;213:114425.

[66] KangT, ZhuQ, WeiD, et al. Nanoparticles coated with neutrophil membranes can effectively treat cancer metastasis. ACS Nano. 2017;11(2):1397-1411.

[67] HanD, WangF, QiaoZ, et al. Neutrophil membrane-camouflaged nanoparticles alleviate inflammation and promote angiogenesis in ischemic myocardial injury. Bioactive Materials. 2023;23:369-382.

[68] CaoX, HuY, LuoS, et al. Neutrophil-mimicking therapeutic nanoparticles for targeted chemotherapy of pancreatic carcinoma. Acta Pharm Sin B. 2019;9(3):575-589.

[69] ZengW, WangY, ZhangQ, et al. Neutrophil nanodecoys inhibit tumor metastasis by blocking the interaction between tumor cells and neutrophils. ACS Nano. 2024;18(10):7363-7378.

[70] ChughV, Vijaya Krishna K, PanditA. Cell membrane-coated mimics: a methodological approach for fabrication, characterization for therapeutic applications, and challenges for clinical translation. ACS Nano. 2021;15(11):17080-17123.

[71] WuY, WanS, YangS, et al. Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment. J Nanobiotechnology. 2022;20(1):542.

[72] ZhaoH, LiL, ZhangJ, et al. C–C chemokine ligand 2 (CCL2) recruits macrophage-membrane-camouflaged hollow bismuth selenide nanoparticles to facilitate photothermal sensitivity and inhibit lung metastasis of breast cancer. ACS Appl Mater Interfaces. 2018;10(37):31124-31135.

[73] QianB-Z, LiJ, ZhangH, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222-225.

[74] CaoH, DanZ, HeX, et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano. 2016;10(8):7738-7748.

[75] LiR, ChenL, JiQ, et al. Macrophage membrane-coated nanoparticles sensitize glioblastoma to radiation by suppressing Proneural–mesenchymal transformation in glioma stem cells. Adv Funct Mater. 2023;33(37):e2213292.

[76] YangC, MingY, ZhouK, et al. Macrophage membrane-camouflaged shRNA and doxorubicin: a pH-Dependent release system for melanoma chemo-immunotherapy. Research. 2022;2022:9768687.

[77] WenX, XiongX, YangG, et al. A macrophage membrane-coated mesoporous silica nanoplatform inhibiting adenosine A2AR via in situ oxygen supply for immunotherapy. J Controlled Release. 2023;353:535-548.

[78] HuangX, WangL, GuoH, ZhangW. Macrophage membrane-coated nanovesicles for dual-targeted drug delivery to inhibit tumor and induce macrophage polarization. Bioactive Materials. 2023;23:69-79.

[79] ParodiA, Quattrocchi N, van de VenAL, et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol. 2013;8(1):61-68.

[80] LopesJ, LopesD, Pereira-SilvaM, et al. Macrophage cell membrane-cloaked nanoplatforms for biomedical applications. Small Methods. 2022;6(8):2200289.

[81] LiB, WangW, ZhaoL, et al. Photothermal therapy of tuberculosis using targeting pre-activated macrophage membrane-coated nanoparticles. Nat Nanotechnol. 2024;19:834-845.

[82] CaoZ, LiuX, ZhangW, et al. Biomimetic macrophage membrane-camouflaged nanoparticles induce ferroptosis by promoting mitochondrial damage in glioblastoma. ACS Nano. 2023;17(23):23746-23760.

[83] YaoQ, YeJ, ChenY, et al. Modulation of glucose metabolism through macrophage-membrane-coated metal-organic framework nanoparticles for triple-negative breast cancer therapy. Chem Eng J. 2024;480:148069.

[84] PanY, WuX, LiuL, et al. Genetically engineered cytomembrane nanovaccines for cancer immunotherapy. Adv Healthcare Mater. 2024;13(13):e2400068.

[85] ZhangJ, SunX, XuM, et al. A self-amplifying ROS-sensitive prodrug-based nanodecoy for circumventing immune resistance in chemotherapy-sensitized immunotherapy. Acta Biomater. 2022;149:307-320.

[86] ChenC, SongM, DuY, et al. Tumor-associated-macrophage-membrane-coated nanoparticles for improved photodynamic immunotherapy. Nano Lett. 2021;21(13):5522-5531.

[87] GaudinoSJ, KumarP. Cross-talk between antigen presenting cells and T cells impacts intestinal homeostasis, bacterial infections, and tumorigenesis. Front Immunol. 2019;10:360.

[88] PatelSA, MinnAJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 2018;48(3):417-433.

[89] WangS, SongY, CaoK, et al. Photothermal therapy mediated by gold nanocages composed of anti-PDL1 and galunisertib for improved synergistic immunotherapy in colorectal cancer. Acta Biomater. 2021;134:621-632.

[90] KangM, HongJ, JungM, et al. T cell-mimicking nanoparticles for cancer immunotherapy. Adv Mater. 2020;32(39):e2003368.

[91] LiuT, ZhouZ, ZhangM, et al. Cuproptosis-immunotherapy using PD-1 overexpressing T cell membrane-coated nanosheets efficiently treats tumor. J Controlled Release. 2023;362:502-512.

[92] LiL, ZhangM, LiJ, et al. Cholesterol removal improves performance of a model biomimetic system to co-deliver a photothermal agent and a STING agonist for cancer immunotherapy. Nat Commun. 2023;14(1):5111.

[93] HanY, PanH, LiW, et al. T cell membrane mimicking nanoparticles with bioorthogonal targeting and immune recognition for enhanced photothermal therapy. Adv Sci. 2019;6(15):e1900251.

[94] LiY, ZhangX, LiuX, PanW, LiN, TangB. A mineralization strategy based on T cell membrane coated CaCO3 nanoparticles against breast cancer and metastasis. Mater Chem Front. 2021;5(15):5738-5745.

[95] MorgadoS, Sanchez-Correa B, CasadoJG, et al. NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions. J Innate Immun. 2011;3(4):365-373.

[96] BottinoC, Castriconi R, PendeD, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198(4):557-567.

[97] DengG, SunZ, LiS, et al. Cell-membrane immunotherapy based on natural killer cell membrane coated nanoparticles for the effective inhibition of primary and abscopal tumor growth. ACS Nano. 2018;12(12):12096-12108.

[98] LiangX, LiL, LiX, et al. A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response. Theranostics. 2021;11(14):6936-6949.

[99] GiovanelliP, Sandoval TA, Cubillos-RuizJR. Dendritic cell metabolism and function in tumors. Trends Immunol. 2019;40(8):699-718.

[100] WangY, XiangY, XinVW, et al. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020;13(1):107.

[101] ArgüelloRJ, Reverendo M, GattiE, PierreP. Regulation of protein synthesis and autophagy in activated dendritic cells: implications for antigen processing and presentation. Immunol Rev. 2016;272(1):28-38.

[102] NizzoliG, Krietsch J, WeickA, et al. Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T cell responses. Blood. 2013;122(6):932-942.

[103] Martínez-LópezM, IborraS, Conde-Garrosa R, SanchoD. Batf3-dependent CD103+ dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice. Eur J Immunol. 2015;45(1):119-129.

[104] FritzJM, Lenardo MJ. Development of immune checkpoint therapy for cancer. J Exp Med. 2019;216(6):1244-1254.

[105] XiaoP, WangJ, ZhaoZ, et al. Engineering nanoscale artificial antigen-presenting cells by metabolic dendritic cell labeling to potentiate cancer immunotherapy. Nano Lett. 2021;21(5):2094-2103.

[106] MaX, KuangL, YinY, et al. Tumor–antigen activated dendritic cell membrane-coated biomimetic nanoparticles with orchestrating immune responses promote therapeutic efficacy against glioma. ACS Nano. 2023;17(3):2341-2355.

[107] CaoY, LongJ, SunH, et al. Dendritic cell-mimicking nanoparticles promote mRNA delivery to lymphoid organs. Adv Sci. 2023;10(33):e2302423.

[108] SunZ, DengG, PengX, et al. Intelligent photothermal dendritic cells restart the cancer immunity cycle through enhanced immunogenic cell death. Biomaterials. 2021;279:121228.

[109] ZhangJ, FanB, CaoG, et al. Direct presentation of tumor-associated antigens to induce adaptive immunity by personalized dendritic cell-mimicking nanovaccines. Adv Mater. 2022;34(47):e2205950.

[110] GongL, ZhangY, ZhaoJ, et al. All-in-one biomimetic nanoplatform based on hollow polydopamine nanoparticles for synergistically enhanced radiotherapy of colon cancer. Small. 2022;18(14):e2107656.

[111] LuY, FanL, WangJ, et al. Cancer cell membrane-based materials for biomedical applications. Small. 2024;20(7):e2306540.

[112] JiaX, YanB, TianX, et al. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy. Int J Biol Sci. 2021;17(13):3281-3287.

[113] GlinskiiOV, SudS, MossineVV, et al. Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-l-leucine. Neoplasia. 2012;14(1):65-73.

[114] KhaldoyanidiSK, Glinsky VV, SikoraL, et al. MDA-MB-435 human breast carcinoma cell homo-and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem. 2003;278(6):4127-4134.

[115] Yahyazadeh MashhadiSM, Kazemimanesh M, ArashkiaA, et al. Shedding light on the EpCAM: an overview. J Cell Physiol. 2019;234(8):12569-12580.

[116] ChenJ, ZhuZ, PanQ, BaiY, YuM, ZhouY. Targeted therapy of oral squamous cell carcinoma with cancer cell membrane coated Co-Fc nanoparticles via autophagy inhibition. Adv Funct Mater. 2023;33(24):e2300235.

[117] LuoG, LiX, LinJ, et al. Multifunctional calcium–manganese nanomodulator provides antitumor treatment and improved immunotherapy via reprogramming of the tumor microenvironment. ACS Nano. 2023;17(16):15449-15465.

[118] SunH, SuJ, MengQ, et al. Cancer-cell-biomimetic nanoparticles for targeted therapy of homotypic tumors. Adv Mater. 2016;28(43):9581-9588.

[119] JanaD, HeB, ChenY, Liu J, ZhaoY. A defect-engineered nanozyme for targeted NIR-II photothermal immunotherapy of cancer. Adv Mater. 2024;36(10):e2206401.

[120] TangY, BisoyiHK, ChenX-M, et al. Pyroptosis-mediated synergistic photodynamic and photothermal immunotherapy enabled by a tumor-membrane-targeted photosensitive dimer. Adv Mater. 2023;35(25):e2300232.

[121] DengJ, XuW, LeiS, et al. Activated natural killer cells-dependent dendritic cells recruitment and maturation by responsive nanogels for targeting pancreatic cancer immunotherapy. Small. 2022;18(44):e2203114.

[122] LiS, JiangS, RahmanMSU, et al. Pre-induced ICD membrane-coated carrier-free nanoparticles for the personalized lung cancer immunotherapy. Small Methods. 2023;7(5):2201569.

[123] WangY, QiuY, ChenS, et al. Functionalized tumor cell membrane-camouflaged photo-activatable nanoparticle for spatiotemporal antitumor therapy. Chem Eng J. 2023;474:145676.

[124] GongM, HuangY, FengH, et al. A nanodrug combining CD47 and sonodynamic therapy efficiently inhibits osteosarcoma deterioration. J Controlled Release. 2023;355:68-84.

[125] GanJ, DuG, HeC, et al. Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination. J Controlled Release. 2020;326:297-309.

[126] XiaoL, HuangY, YangY, et al. Biomimetic cytomembrane nanovaccines prevent breast cancer development in the long term. Nanoscale. 2021;13(6):3594-3601.

[127] FangRH, HuC-MJ, LukBT, et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 2014;14(4):2181-2188.

[128] WuM, LiuX, BaiH, et al. Surface-layer protein-enhanced immunotherapy based on cell membrane-coated nanoparticles for the effective inhibition of tumor growth and metastasis. ACS Appl Mater Interfaces. 2019;11(10):9850-9859.

[129] ToyofukuM, NomuraN, EberlL. Types and origins of bacterial membrane vesicles. Nat Rev Microbiol. 2019;17(1):13-24.

[130] NagakuboT, NomuraN, ToyofukuM. Cracking open bacterial membrane vesicles. Front Microbiol. 2020;10:3026.

[131] LiM, ZhouH, YangC, et al. Bacterial outer membrane vesicles as a platform for biomedical applications: an update. J Controlled Release. 2020;323:253-268.

[132] CaoZ, LiuJ. Bacteria and bacterial derivatives as drug carriers for cancer therapy. J Controlled Release. 2020;326:396-407.

[133] ToyofukuM, SchildS, Kaparakis-LiaskosM, EberlL. Composition and functions of bacterial membrane vesicles. Nat Rev Microbiol. 2023;21(7):415-430.

[134] LiuG, MaN, ChengK, et al. Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity. Nature Nanotechnology. 2023;19(3):387-398.

[135] Mat RaniNNI, Alzubaidi ZM, ButtAM, et al. Outer membrane vesicles as biomimetic vaccine carriers against infections and cancers. WIREs Nanomed Nanobiotechnol. 2022;14(4):e1784.

[136] GerritzenMJH, Martens DE, WijffelsRH, van der PolL, StorkM. Bioengineering bacterial outer membrane vesicles as vaccine platform. Biotech Adv. 2017;35(5):565-574.

[137] ChenX, LiP, LuoB, et al. Surface mineralization of engineered bacterial outer membrane vesicles to enhance tumor photothermal/immunotherapy. ACS Nano. 2024;18(2):1357-1370.

[138] TanK, LiR, HuangX, Liu Q. Outer membrane vesicles: current status and future direction of these novel vaccine adjuvants. Front Microbiol. 2018;9:00783.

[139] ChenW, SongY, BaiS, et al. Cloaking mesoporous polydopamine with bacterial membrane vesicles to amplify local and systemic antitumor immunity. ACS Nano. 2023;17(8):7733-7749.

[140] HeY, PanY, ZhaoX, et al. Camouflaging multifunctional nanoparticles with bacterial outer membrane for augmented chemodynamic/photothermal/starvation/chemo multimodal synergistic therapy of orthotopic glioblastoma. Chem Eng J. 2023;471:144410.

[141] ZhuangW-R, WangY, NieW, et al. Bacterial outer membrane vesicle based versatile nanosystem boosts the efferocytosis blockade triggered tumor-specific immunity. Nat Commun. 2023;14(1):1675.

[142] BenneN, van Duijn J, KuiperJ, JiskootW, Slütter B. Orchestrating immune responses: how size, shape and rigidity affect the immunogenicity of particulate vaccines. J Controlled Release. 2016;234:124-134.

[143] TikuV, TanM-W. Host immunity and cellular responses to bacterial outer membrane vesicles. Trends Immunol. 2021;42(11):1024-1036.

[144] ZhouS, Gravekamp C, BermudesD, LiuK. Tumour-targeting bacteria engineered to fight cancer. Nat Rev Cancer. 2018;18(12):727-743.

[145] ZhaoY, LiA, JiangL, Gu Y, LiuJ. Hybrid membrane-coated biomimetic nanoparticles (HM@BNPs):a multifunctional nanomaterial for biomedical applications. Biomacromolecules. 2021;22(8):3149-3167.

[146] XiongJ, WuM, ChenJ, et al. Cancer-erythrocyte hybrid membrane-camouflaged magnetic nanoparticles with enhanced photothermal-immunotherapy for ovarian cancer. ACS Nano. 2021;15(12):19756-19770.

[147] ZhangT, LiuH, LiL, et al. Leukocyte/platelet hybrid membrane-camouflaged dendritic large pore mesoporous silica nanoparticles co-loaded with photo/chemotherapeutic agents for triple negative breast cancer combination treatment. Bioactive Materials. 2021;6(11):3865-3878.

[148] ShengS, JinL, ZhangY, et al. A twindrive precise delivery system of platelet-neutrophil hybrid membrane regulates macrophage combined with CD47 blocking for postoperative immunotherapy. ACS Nano. 2024;18(6):4981-4992.

[149] ChenZ, GuoW, TanL, et al. Biomimetic MOF-based nano-immunoactivator via disruption of ion homeostasis for strengthened tumor microwave-immunotherapy. Adv Funct Mater. 2024;34(36):e2401359.

[150] YinY, TangW, MaX, et al. Biomimetic neutrophil and macrophage dual membrane-coated nanoplatform with orchestrated tumor-microenvironment responsive capability promotes therapeutic efficacy against glioma. Chem Eng J. 2022;433:133848.

[151] JiP, DengX-C, JinX-K, et al. Fused cytomembrane-camouflaged nanoparticles for tumor-specific immunotherapy. Adv Healthcare Mater. 2023;12(23):e2300323.

[152] WangD, LiuC, YouS, et al. Bacterial vesicle-cancer cell hybrid membrane-coated nanoparticles for tumor specific immune activation and photothermal therapy. ACS Appl Mater Interfaces. 2020;12(37):41138-41147.

[153] PanP, DongX, ChenY, Ye J-J, SunY-X, ZhangX-Z. A heterogenic membrane-based biomimetic hybrid nanoplatform for combining radiotherapy and immunotherapy against breast cancer. Biomaterials. 2022;289:121810.

[154] GoS, JungM, LeeS, et al. A personalized cancer nanovaccine that enhances T cell responses and efficacy through dual interactions with dendritic cells and T cells. Adv Mater. 2023;35(49):e2303979.

[155] WangZ, ChenC, ShiC, et al. Cell membrane derived liposomes loaded with DNase I target neutrophil extracellular traps which inhibits colorectal cancer liver metastases. J Controlled Release. 2023;357:620-629.

[156] HuangH, SunM, LiuM, et al. Full encapsulation of oncolytic virus using hybrid erythroctye-liposome membranes for augmented anti-refractory tumor effectiveness. Nano Today. 2022;47:101671.

[157] WuP, JiangX, YinS, YangY, LiuT, WangK. Biomimetic recombinant of red blood cell membranes for improved photothermal therapy. J Nanobiotechnology. 2021;19(1):213.

[158] KimS-J, ParkH-B, AnE-K, et al. Artificial immunogenic cell death lipid nanoparticle functions as a therapeutic vaccine for cancer. Adv Funct Mater. 2023;33(31):e2302825.

[159] XuC, JiangY, HanY, PuK, ZhangR. A polymer multicellular nanoengager for synergistic NIR-II photothermal immunotherapy. Adv Mater. 2021;33(14):e2008061.

[160] DingC, ZhangC, ChengS, Xian Y. Multivalent aptamer functionalized Ag2S Nanodots/hybrid cell membrane-coated magnetic nanobioprobe for the ultrasensitive isolation and detection of circulating tumor cells. Adv Funct Mater. 2020;30(16):e1909781.

[161] RenH, LiJ, ZhangJ, et al. Anti-tumor immunity induced by a ternary membrane system derived from cancer cells, dendritic cells, and bacteria. Small. 2023;19(50):e2302756.

[162] HuangX, MuN, DingY, et al. Tumor microenvironment targeting for glioblastoma multiforme treatment via hybrid cell membrane coating supramolecular micelles. J Controlled Release. 2024;366:194-203.

[163] WangL, LiuJ. Engineered drug-loaded cells and cell derivatives as a delivery platform for cancer immunotherapy. Biomater Sci. 2021;9(4):1104-1116.

[164] ZhangF, LiF, LuG-H, et al. Engineering magnetosomes for ferroptosis/immunomodulation synergism in cancer. ACS Nano. 2019;13(5):5662-5673.

[165] LiF, NieW, ZhangF, et al. Engineering magnetosomes for high-performance cancer vaccination. ACS Cent Sci. 2019;5(5):796-807.

[166] LiuC, ZhouY, GuoD, et al. Reshaping intratumoral mononuclear phagocytes with antibody-opsonized immunometabolic nanoparticles. Adv Sci. 2023;10(34):e2303298.

[167] ChengQ, KangY, YaoB, et al. Genetically engineered-cell-membrane nanovesicles for cancer immunotherapy. Adv Sci. 2023;10(26):e2302131.

[168] SunZ, LiuJ, LiY, et al. Aggregation-induced-emission photosensitizer-loaded nano-superartificial dendritic cells with directly presenting tumor antigens and reversed immunosuppression for photodynamically boosted immunotherapy. Adv Mater. 2023;35(3):e2208555.

[169] YinT, FanQ, HuF, et al. Engineered macrophage-membrane-coated nanoparticles with enhanced PD-1 expression induce immunomodulation for a synergistic and targeted antiglioblastoma activity. Nano Lett. 2022;22(16):6606-6614.

[170] DuanY, ZhouJ, ZhouZ, et al. Extending the in vivo residence time of macrophage membrane-coated nanoparticles through genetic modification. Small. 2023;19(52):e2305551.

[171] YamanS, Ramachandramoorthy H, IyerP, et al. Targeted chemotherapy via HER2-based chimeric antigen receptor (CAR) engineered T cell membrane coated polymeric nanoparticles. Bioactive Materials. 2024;34:422-435.

[172] TangQ, SunS, WangP, et al. Genetically engineering cell membrane-coated BTO nanoparticles for MMP2-activated piezocatalysis-immunotherapy. Adv Mater. 2023;35(18):2300964.

[173] WangK, ZhangX, YeH, et al. Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and safe cancer immunotherapy. Nat Commun. 2023;14(1):6748.

[174] FengQ, MaX, ChengK, et al. Engineered bacterial outer membrane vesicles as controllable two-way adaptors to activate macrophage phagocytosis for improved tumor immunotherapy. Adv Mater. 2022;34(40):e2206200.

[175] LiY, ZhaoR, ChengK, et al. Bacterial outer membrane vesicles presenting programmed death 1 for improved cancer immunotherapy via immune activation and checkpoint inhibition. ACS Nano. 2020;14(12):16698-16711.

[176] ZhaoC, PanY, YuG, ZhaoX-Z, ChenX, Rao L. Vesicular antibodies: shedding light on antibody therapeutics with cell membrane nanotechnology. Adv Mat. 2023;12(35):e2207875.

[177] OroojalianF, BeygiM, BaradaranB, Mokhtarzadeh A, ShahbaziMA. Immune cell membrane-coated biomimetic nanoparticles for targeted cancer therapy. Small. 2021;17(12):e2006484.

[178] LukBT, Jack Hu CM, FangRH, et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale. 2014;6(5):2730-2737.

[179] HuCMJ, FangRH, LukBT, et al. Marker-of-self’ functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale. 2013;5(7):2664-2668.

[180] XuCH, YePJ, ZhouYC, He DX, WeiH, YuCY. Cell membrane-camouflaged nanoparticles as drug carriers for cancer therapy. Acta Biomater. 2020;105:1-14.

[181] XiaQ, ZhangY, LiZ, HouX, FengN. Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application. Acta Pharm Sin B. 2019;9(4):675-689.

[182] ZhaiY, SuJ, RanW, et al. Preparation and application of cell membrane-camouflaged nanoparticles for cancer therapy. Theranostics. 2017;7(10):2575-2592.

[183] LiZ, CaiH, LiZ, et al. A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody. Bioactive Materials. 2023;21:299-312.

[184] FangRH, GaoW, ZhangL. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat Rev Clin Oncol. 2023;20(1):33-48.

[185] RodriguesCF, Fernandes N, de Melo-DiogoD, CorreiaIJ, Moreira AF. Cell-derived vesicles for nanoparticles’ coating: biomimetic approaches for enhanced blood circulation and cancer therapy. Adv Healthcare Mater. 2022;11(23):e2201214.

[186] WangF, LinS, YuZ, et al. Recent advances in microfluidic-based electroporation techniques for cell membranes. Lab Chip. 2022;22(14):2624-2646.

[187] RaoL, CaiB, BuL-L, et al. Microfluidic electroporation-facilitated synthesis of erythrocyte membrane-coated magnetic nanoparticles for enhanced imaging-guided cancer therapy. ACS Nano. 2017;11(4):3496-3505.

[188] RaoL, BuL-L, MaL, et al. Platelet-facilitated photothermal therapy of head and neck squamous cell carcinoma. Angew Chem Int Ed. 2018;57(4):986-991.

[189] Ben-AkivaE, MeyerRA, YuH, SmithJT, PardollDM, Green JJ. Biomimetic anisotropic polymeric nanoparticles coated with red blood cell membranes for enhanced circulation and toxin removal. Sci Adv. 2020;6(16):eaay9035.

[190] WangC, WuB, WuY, SongX, ZhangS, Liu Z. Camouflaging nanoparticles with brain metastatic tumor cell membranes: a new strategy to traverse blood–brain barrier for imaging and therapy of brain tumors. Adv Funct Mater. 2020;30(14):e1909369.

[191] RaoL, BuL-L, CaiB, et al. Cancer cell membrane-coated upconversion nanoprobes for highly specific tumor imaging. Adv Mater. 2016;28(18):3460-3466.

[192] ChenH, ZhengD, PanW, et al. Biomimetic nanotheranostics camouflaged with cancer cell membranes integrating persistent oxygen supply and homotypic targeting for hypoxic tumor elimination. ACS Appl Mater Interfaces. 2021;13(17):19710-19725.

[193] TangJ, ShenD, CaranasosTG, et al. Therapeutic microparticles functionalized with biomimetic cardiac stem cell membranes and secretome. Nat Commun. 2017;8(1):13724.

[194] ZhangX, ZhenX, YangY, Feng Q, YuanW, XieX. Precise assembly of inside-out cell membrane camouflaged nanoparticles via bioorthogonal reactions for improving drug leads capturing. Acta Pharm Sin B. 2023;13(2):852-862.

[195] XieW, DengW-W, ZanM, et al. Cancer cell membrane camouflaged nanoparticles to realize starvation therapy together with checkpoint blockades for enhancing cancer therapy. ACS Nano. 2019;13(3):2849-2857.

[196] FuL, ZhangW, ZhouX, Fu J, HeC. Tumor cell membrane-camouflaged responsive nanoparticles enable MRI-guided immuno-chemodynamic therapy of orthotopic osteosarcoma. Bioactive Materials. 2022;17:221-233.

[197] GaoW, HuC-MJ, FangRH, Luk BT, SuJ, ZhangL. Surface functionalization of gold nanoparticles with red blood cell membranes. Adv Mater. 2013;25(26):3549-3553.

[198] WuZ, LiT, GaoW, et al. Cell-membrane-coated synthetic nanomotors for effective biodetoxification. Adv Funct Mater. 2015;25(25):3881-3887.

[199] ChenDS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10.

[200] ZhouB, LiuJ, LinM, ZhuJ, ChenWR. Recent advances in immunotherapy, immunoadjuvant, and nanomaterial-base. combination immunotherapy. Coord Chem Rev. 2021;442:214009.

[201] LiD, LiuS, MaY, LiuS, LiuY, DingJ. Biomaterials that induce immunogenic cell death. Small Methods. 2023;7(5):2300204.

[202] HeT, HuM, ZhuS, et al. A tactical nanomissile mobilizing antitumor immunity enables neoadjuvant chemo-immunotherapy to minimize postsurgical tumor metastasis and recurrence. Acta Pharm Sin B. 2023;13(2):804-818.

[203] GuoJ, ZouY, HuangL. Nano delivery of chemotherapeutic ICD inducers for tumor immunotherapy. Small Methods. 2023;7(5):2201307.

[204] LiX, LuoR, LiangX, Wu Q, GongC. Recent advances in enhancing reactive oxygen species based chemodynamic therapy. Chin Chem Lett. 2022;33(5):2213-2230.

[205] ZhangL, ZhangY, WangX, et al. A Trojan-horse-like biomimetic nano-NK to elicit an immunostimulatory tumor microenvironment for enhanced GBM Chemo-Immunotherapy. Small. 2023;19(44):2301439.

[206] YaoY, ChenH, TanN. Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy. Acta Pharm Sin B. 2022;12(4):2103-2119.

[207] ZouY, WangY, XuS, et al. Brain co-delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy. Adv Mater. 2022;34(33):e2203958.

[208] QiaoC, WangX, LiuG, et al. Erythrocyte membrane camouflaged metal–organic framework nanodrugs for remodeled tumor microenvironment and enhanced tumor chemotherapy. Adv Funct Mater. 2022;32(6):e2107791.

[209] WangX, HuangR, WuW, et al. Amplifying STING activation by bioinspired nanomedicine for targeted chemo-and immunotherapy of acute myeloid leukemia. Acta Biomater. 2023;157:381-394.

[210] GuoY, FanY, WangZ, et al. Chemotherapy mediated by biomimetic polymeric nanoparticles potentiates enhanced tumor immunotherapy via amplification of endoplasmic reticulum stress and mitochondrial dysfunction. Adv Mater. 2022;34(47):e2206861.

[211] CuiJ, ZhangF, YanD, et al. “Trojan horse” phototheranostics: fine-engineering NIR-II AIEgen camouflaged by cancer cell membrane for homologous-targeting multimodal imaging-guided phototherapy. Adv Mater. 2023;35(33):e2302639.

[212] GaoJ, QinH, WangF, et al. Hyperthermia-triggered biomimetic bubble nanomachines. Nat Commun. 2023;14(1):4867.

[213] PatelRB, YeM, CarlsonPM, et al. Development of an in situ cancer vaccine via combinational radiation and bacterial-membrane-coated nanoparticles. Adv Mater. 2019;31(43):1902626.

[214] LiuJ, ShiJ, NieW, WangS, LiuG, CaiK. Recent progress in the development of multifunctional nanoplatform for precise tumor phototherapy. Adv Healthcare Mater. 2021;10(1):e2001207.

[215] LiT, ChenG, XiaoZ, et al. Surgical tumor-derived photothermal nanovaccine for personalized cancer therapy and prevention. Nano Lett. 2022;22(7):3095-3103.

[216] ChenY, ZhiS, OuJ, et al. Cancer cell membrane-coated nanoparticle co-loaded with photosensitizer and toll-like receptor 7 agonist for the enhancement of combined tumor immunotherapy. ACS Nano. 2023;17(17):16620-16632.

[217] HuangH, LiN, WeiX, et al. Biomimetic “gemini nanoimmunoregulators” orchestrated for boosted photoimmunotherapy by spatiotemporally modulating PD-L1 and tumor-associated macrophages. Acta Pharm Sin B. 2024;14(3):1345-1361.

[218] WeiX, HuangH, GuoJ, et al. Biomimetic nano-immunoactivator via ionic metabolic modulation for strengthened NIR-II photothermal immunotherapy. Small. 2023;19(49):e2304370.

[219] LiW, FanJ-X, ZhengD-W, Zhang X-Z. Tumor antigen loaded nanovaccine induced NIR-Activated inflammation for enhanced antigen presentation during immunotherapy of tumors. Small. 2022;18(49):e2205193.

[220] YuG-T, RaoL, WuH, et al. Myeloid-derived suppressor cell membrane-coated magnetic nanoparticles for cancer theranostics by inducing macrophage polarization and synergizing immunogenic cell death. Adv Funct Mater. 2018;28(37):e1801389.

[221] GaoG, SunX, LiangG. Nanoagent-promoted mild-temperature photothermal therapy for cancer treatment. Adv Funct Mater. 2021;31(25):e2100738.

[222] HuangX, LiL, OuC, et al. Tumor environment regression therapy implemented by switchable Prune-to-Essence nanoplatform unleashed systemic immune responses. Adv Sci. 2023;10(35):e2303715.

[223] ChenQ, HuangG, WuW, et al. A hybrid eukaryotic–prokaryotic nanoplatform with photothermal modality for enhanced antitumor vaccination. Adv Mater. 2020;32(16):e1908185.

[224] ShiY, ZhuD, WangD, et al. RecentadvancesofsmartAIEgens for photoacoustic imaging and phototherapy. Coord Chem Rev. 2022;471:214725.

[225] YangX, YangT, LiuQ, et al. Biomimetic aggregation-induced emission nanodots with hitchhiking function for T cell-mediated cancer targeting and NIR-II fluorescence-guided mild-temperature photothermal therapy. Adv Funct Mater. 2022;32(45):e2206346.

[226] LanM, ZhaoS, LiuW, LeeC-S, ZhangW, Wang P. Photosensitizers for photodynamic therapy. Adv Healthcare Mater. 2019;8(13):e1900132.

[227] YangJ, BaiL, ShenM, et al. A multiple stimuli-responsive nanoCRISPR overcomes tumor redox heterogeneity to augment photodynamic therapy. ACS Nano. 2023;17(12):11414-11426.

[228] ZhuangW-R, WangY, LeiY, et al. Phytochemical engineered bacterial outer membrane vesicles for photodynamic effects promoted immunotherapy. Nano Lett. 2022;22(11):4491-4500.

[229] XuX, DengG, SunZ, et al. A biomimetic aggregation-induced emission photosensitizer with antigen-presenting and hitchhiking function for lipid droplet targeted photodynamic immunotherapy. Adv Mater. 2021;33(33):e2102322.

[230] XieF, LiuZ, WangP, et al. Self-delivering nanodrugs developed via small-molecule-directed assembly and macrophage cloaking for sonodynamic-augmented immunotherapy. Adv Healthcare Mater. 2022;11(16):e2102770.

[231] ZhangY, ZhangY, LiY, et al. Harnessing Ag2S quantum dots with immune adjuvant for NIR-II fluorescence imaging-guided sonodynamic immunotherapy of colon cancer. Chem Eng J. 2023;474:145685.

[232] SunW, JiP, ZhouT, et al. Ultrasound responsive nanovaccine armed with engineered cancer cell membrane and RNA to prevent foreseeable metastasis. Adv Sci. 2023;10(19):e2301107.

[233] LiQ, SuR, BaoX, et al. Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy. Acta Biomater. 2022;144:109-120.

[234] QiaoB, LuoY, ChengH-B, et al. Artificial nanotargeted cells with stable photothermal performance for multimodal imaging-guided tumor-specific therapy. ACS Nano. 2020;14(10):12652-12667.

[235] XuW, LiD, ChenC, Wang J, WeiX, YangX. Design of mitoxantrone-loaded biomimetic nanocarrier with sequential photothermal/photodynamic/chemotherapy effect for synergized immunotherapy. Adv Funct Mater. 2023;33(40):e2302231.

[236] KangX, ZhangY, SongJ, et al. A photo-triggered self-accelerated nanoplatform for multifunctional image-guided combination cancer immunotherapy. Nat Commun. 2023;14(1):5216.

[237] LuZ, BaiS, JiangY, et al. Amplifying dendritic cell activation by bioinspired nanometal organic frameworks for synergistic sonoimmunotherapy. Small. 2022;18(44):e2203952.

[238] TangS, NingQ, YangL, Mo Z, TangS. Mechanisms of immune escape in the cancer immune cycle. Int Immunopharmacol. 2020;86:106700.

[239] FritahH, Rovelli R, ChiangCL-L, KandalaftLE. The current clinical landscape of personalized cancer vaccines. Cancer Treat Rev. 2022;106:102383.

[240] XuJ, LvJ, ZhuangQ, et al. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat Nanotechnol. 2020;15(12):1043-1052.

[241] RaoL, YuG-T, MengQ-F, et al. Cancer cell membrane-coated nanoparticles for personalized therapy in patient-derived xenograft models. Adv Funct Mater. 2019;29(51):e1905671.

[242] XueY, CheJ, JiX, LiY, XieJ, ChenX. Recent advances in biomaterial-boosted adoptive cell therapy. Chem Soc Rev. 2022;51(5):1766-1794.

[243] XiaoP, WangJ, FangL, et al. Nanovaccine-mediated cell selective delivery of neoantigens potentiating adoptive dendritic cell transfer for personalized immunization. Adv Funct Mater. 2021;31(36):e2104068.

[244] ZhangY, ChenJ, ShiL, MaF. Polymeric nanoparticle-based nanovaccines for cancer immunotherapy. Materials Horizons. 2023;10:361-392.

[245] KrollAV, FangRH, JiangY, et al. Nanoparticulate delivery of cancer cell membrane elicits multiantigenic antitumor immunity. Adv Mater. 2017;29(47):e1703969.

[246] LiS, FengX, WangJ, et al. Multiantigenic nanoformulations activate anticancer immunity depending on size. Adv Funct Mater. 2019;29(49):e1903391.

[247] YangR, XuJ, XuL, et al. Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination. ACS Nano. 2018;12(6):5121-5129.

[248] TuoZ, HeQ, ZhangZ, et al. Irradiation conditioning of adjuvanted, autologous cancer cell membrane nanoparticle vaccines. Chem Eng J. 2022;433:134437.

[249] LiuQ, HuY, ZhengP, et al. Exploiting immunostimulatory mechanisms of immunogenic cell death to develop membrane-encapsulated nanoparticles as a potent tumor vaccine. J Nanobiotechnology. 2023;21(1):326.

[250] LiuS, WuJ, FengY, et al. CD47KO/CRT dual-bioengineered cell membrane-coated nanovaccine combined with anti-PD-L1 antibody for boosting tumor immunotherapy. Bioactive Materials. 2023;22:211-224.

[251] LiY, ZhangH, WangR, et al. Tumor cell nanovaccines based on genetically engineered antibody-anchored membrane. Adv Mater. 2023;35(13):e2208923.

[252] ChenL, QinH, ZhaoR, et al. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines. Sci Transl Med. 2021;13(601):eabc2816.

[253] LiY, MaX, YueY, et al. Rapid surface display of mRNA antigens by bacteria-derived outer membrane vesicles for a personalized tumor vaccine. Adv Mater. 2022;34(20):e2109984.

[254] Van HerckS, FengB, TangL. Delivery of STING agonists for adjuvanting subunit vaccines. Adv Drug Deliv Rev. 2021;179:114020.

[255] KrishnanN, Kubiatowicz LJ, HolayM, ZhouJ, FangRH, ZhangL. Bacterial membrane vesicles for vaccine applications. Adv Drug Deliv Rev. 2022;185:114294.

[256] KeY, ZhuJ, ChuY, et al. Bifunctional fusion membrane-based hydrogel enhances antitumor potency of autologous cancer vaccines by activating dendritic cells. Adv Funct Mater. 2022;32(29):e2201306.

[257] KrishnanN, JiangY, ZhouJ, et al A modular approach to enhancing cell membrane-coated nanoparticle functionality using genetic engineering. Nat Nanotechnol. 2024;19(3):345-353.

[258] HuZ, OttPA, WuCJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168-182.

[259] PaluckaK, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265-277.

[260] EggermontLJ, PaulisLE, TelJ, FigdorCG. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells. Trends Biotechnol. 2014;32(9):456-465.

[261] JiangY, Krishnan N, ZhouJ, et al. Engineered cell-membrane-coated nanoparticles directly present tumor antigens to promote anticancer immunity. Adv Mater. 2020;32(30):e2001808.

[262] GongJ, KoidoS, CalderwoodSK. Cell fusion: from hybridoma to dendritic cell-based vaccine. Expert Rev Vaccines. 2008;7(7):1055-1068.

[263] LiuW-L, ZouM-Z, LiuT, et al. Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells. Nat Commun. 2019;10(1):3199.

[264] ZhaoP, XuY, JiW, et al. Hybrid membrane nanovaccines combined with immune checkpoint blockade to enhance cancer immunotherapy. Int J Nanomedicine. 2022;17:73-89.

[265] MaJ, LiuF, SheuWC, et al. Copresentation of tumor antigens and costimulatory molecules via biomimetic nanoparticles for effective cancer immunotherapy. Nano Lett. 2020;20(6):4084-4094.

[266] ChenF, GengZ, WangL, Zhou Y, LiuJ. Biomimetic nanoparticles enabled by cascade cell membrane coating for direct cross-priming of T cells. Small. 2022;18(3):e2104402.

[267] ChengS, XuC, JinY, et al. Artificial mini dendritic cells boost T cell–based immunotherapy for ovarian cancer. Adv Sci. 2020;7(7):e1903301.

[268] LiuC, LiuX, XiangX, et al. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nat Nanotechnol. 2022;17(5):531-540.

[269] ZhangQ, WeiW, WangP, et al. Biomimetic magnetosomes as versatile artificial antigen-presenting cells to potentiate T cell-based anticancer therapy. ACS Nano. 2017;11(11):10724-10732.

[270] SongW, Musetti SN, HuangL. Nanomaterials for cancer immunotherapy. Biomaterials. 2017;148:16-30.

[271] WiederT, Eigentler T, BrennerE, RöckenM. Immune checkpoint blockade therapy. J Allergy Clin Immunol. 2018;142(5):1403-1414.

[272] ZhangX, WangC, WangJ, et al. PD-1 blockade cellular vesicles for cancer immunotherapy. Adv Mater. 2018;30(22):e1707112.

[273] ZhaiY, WangJ, LangT, et al. T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy. Nat Nanotechnol. 2021;16(11):1271-1280.

[274] WorboysJD, VowellKN, HareRK, et al. TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation. Nat Commun. 2023;14(1):5016.

[275] YuY, ChengQ, JiX, et al. Engineered drug-loaded cellular membrane nanovesicles for efficient treatment of postsurgical cancer recurrence and metastasis. Sci Adv. 2022;8(49):eadd3599.

[276] XuY, XiongJ, SunX, GaoH. Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy. Acta Pharm Sin B. 2022;12(12):4327-4347.

[277] ChengY, SongS, WuP, et al. Tumor associated macrophages and TAMs-based anti-tumor nanomedicines. Adv Healthcare Mater. 2021;10(18):e2100590.

[278] Cervantes-VillagranaRD, Albores-García D, Cervantes-VillagranaAR, García-AcevezSJ. Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct Target Ther. 2020;5(1):99.

[279] YueY, LiF, LiY, et al. Biomimetic nanoparticles carrying a repolarization agent of tumor-associated macrophages for remodeling of the inflammatory microenvironment following photothermal therapy. ACS Nano. 2021;15(9):15166-15179.

[280] RaoL, WuL, LiuZ, et al. Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis. Nat Commun. 2020;11(1):4909.

[281] QingS, LyuC, ZhuL, et al. Biomineralized bacterial outer membrane vesicles potentiate safe and efficient tumor microenvironment reprogramming for anticancer therapy. Adv Mater. 2020;32(47):e2002085.

[282] ZangS, HuangK, LiJ, et al. Metabolic reprogramming by dual-targeting biomimetic nanoparticles for enhanced tumor chemo-immunotherapy. Acta Biomater. 2022;148:181-193.

[283] ChenX, SongE. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discovery. 2019;18(2):99-115.

[284] JoshiS, Sharabi A. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. Pharmacol Ther. 2022;235:108114.

[285] LvP, LiuX, ChenX, et al. Genetically engineered cell membrane nanovesicles for oncolytic adenovirus delivery: a versatile platform for cancer virotherapy. Nano Lett. 2019;19(5):2993-3001.

[286] JiaX, WangL, FengX, et al. Cell membrane-coated oncolytic adenovirus for targeted treatment of glioblastoma. Nano Lett. 2023;23(23):11120-11128.

[287] LiuR, CaoZ, WangL, et al. Multimodal oncolytic bacteria by coating with tumor cell derived nanoshells. Nano Today. 2022;45:101537.

[288] CaoZ, ChengS, WangX, Pang Y, LiuJ. Camouflaging bacteria by wrapping with cell membranes. Nat Commun. 2019;10(1):3452.

[289] DengY, JiaF, JiangP, et al. Biomimetic nanoparticle synchronizing pyroptosis induction and mitophagy inhibition for anti-tumor therapy. Biomaterials. 2023;301:122293.

[290] GongH, ZhangQ, KomarlaA, et al. Nanomaterial biointerfacing via mitochondrial membrane coating for targeted detoxification and molecular detection. Nano Lett. 2021;21(6):2603-2609.

[291] ZouY, SunY, WangY, et al. Cancer cell-mitochondria hybrid membrane coated gboxin loaded nanomedicines for glioblastoma treatment. Nat Commun. 2023;14(1):4557.

[292] QiuC, HanH-H, SunJ, et al. Regulating intracellular fate of siRNA by endoplasmic reticulum membrane-decorated hybrid nanoplexes. Nat Commun. 2019;10(1):2702.

[293] HouL, GongX, YangJ, Zhang H, YangW, ChenX. Hybrid-membrane-decorated prussian blue for effective cancer immunotherapy via tumor-associated macrophages polarization and hypoxia relief. Adv Mater. 2022;34(14):e2200389.

[294] LiuL, BaiX, MartikainenM-V, et al. Cell membrane coating integrity affects the internalization mechanism of biomimetic nanoparticles. Nat Commun. 2021;12(1):5726.

[295] YuanP, ChenX, LiX, et al. Effect of cell membrane-cloaked nanoparticle elasticity on Nano-Bio interaction. Small Methods. 2023;7(6):2201548.

[296] LiuL, PanD, ChenS, et al. Systematic design of cell membrane coating to improve tumor targeting of nanoparticles. Nat Commun. 2022;13(1):6181.

[297] TapeinosC, Torrieri G, WangS, MartinsJP, SantosHA. Evaluation of cell membrane-derived nanoparticles as therapeutic carriers for pancreatic ductal adenocarcinoma using an in vitro tumour stroma model. J Controlled Release. 2023;362:225-242.

[298] XieX, HuX, LiQ, et al. Unraveling cell-type-specific targeted delivery of membrane-camouflaged nanoparticles with plasmonic imaging. Nano Lett. 2020;20(7):5228-5235.

[299] MarxV. Closing in on cancer heterogeneity with organoids. Nature Methods. 2024;21(4):551-554.

[300] LiW, ZhouZ, ZhouX, et al. 3D biomimetic models to reconstitute tumor microenvironment in vitro: spheroids, organoids, and tumor-on-a-Chip. Adv Healthcare Mater. 2023;12(18):e2202609.

[301] WuH, ZhangT, LiN, GaoJ. Cell membrane-based biomimetic vehicles for effective central nervous system target delivery: insights and challenges. J Controlled Release. 2023;360:169-184.

[302] ZingerA. Unleashing the potential of cell biomimetic nanoparticles: strategies and challenges in their design and fabrication for therapeutic applications. J Controlled Release. 2023;358:591-600.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm - Biomaterials and Applications published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).